Show simple item record

dc.contributor.authorSuciu, S
dc.contributor.authorEggermont, A
dc.contributor.authorLorigan, Paul C
dc.contributor.authorKirkwood, J
dc.contributor.authorMarkovic, S
dc.contributor.authorGarbe, C
dc.contributor.authorCameron, D
dc.contributor.authorKotapati, S
dc.contributor.authorChen, T
dc.contributor.authorWheatley, K
dc.contributor.authorIves, N
dc.contributor.authorde Schaetzen, G
dc.contributor.authorEfendi, A
dc.contributor.authorBuyse, M
dc.date.accessioned2017-10-23T19:56:24Z
dc.date.available2017-10-23T19:56:24Z
dc.date.issued2018-01-01
dc.identifier.citationRelapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy. 2018, 110 (1): J Natl Cancer Insten
dc.identifier.issn1460-2105
dc.identifier.pmid28922786
dc.identifier.doi10.1093/jnci/djx133
dc.identifier.urihttp://hdl.handle.net/10541/620624
dc.description.abstractWe assessed whether relapse-free survival (RFS; time until recurrence/death) is a valid surrogate for overall survival (OS) among resected stage II-III melanoma patients through a meta-analysis of randomized controlled trials.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of the National Cancer Instituteen
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntineoplastic Agents
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshDisease-Free Survival
dc.subject.meshHumans
dc.subject.meshInterferon-alpha
dc.subject.meshMelanoma
dc.subject.meshNeoplasm Staging
dc.subject.meshRandomized Controlled Trials as Topic
dc.subject.meshSkin Neoplasms
dc.subject.meshSurvival Rate
dc.titleRelapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy.en
dc.typeArticleen
dc.contributor.departmentEuropean Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgiumen
dc.identifier.journalJournal of the National Cancer Instituteen
refterms.dateFOA2018-12-17T15:08:49Z
html.description.abstractWe assessed whether relapse-free survival (RFS; time until recurrence/death) is a valid surrogate for overall survival (OS) among resected stage II-III melanoma patients through a meta-analysis of randomized controlled trials.


Files in this item

Thumbnail
Name:
djx133.pdf
Size:
946.5Kb
Format:
PDF
Description:
Full text, Open Access article

This item appears in the following Collection(s)

Show simple item record